Week In Review: China's Innovent Raises $100 Million For Biologics Portfolio

Innovent Biologics of Suzhou announced a $100 million C round funding that will be used to advance the company's portfolio of eight biologic drug candidates; Hubei Biocause Pharma raised $1.6 billion in a private placement and will spend $1.2 billion to gain control of a life insurance company; Meinian Onehealth Healthcare, a Shanghai-based network of China clinics, invested in Ciming Health Checkup, a rival; Kingworld Medicines will market Sinopharm products through e-business channels; Mitsubishi Gas Chemical and US-based Catalent Pharma formed an Asian biologics CRO partnership; PerkinElmer opened a medical lab in Suzhou to provide prenatal and infectious disease screening in China; the CFDA approved the world's first inactivated Sabin strain polio vaccine, developed by China's Institute of Medical Biology; and China's State Council, to improve rural healthcare in China, announced incentives for rural doctors and liberalized rules for private ownership of hospitals.

Help employers find you! Check out all the jobs and post your resume.

Back to news